Abstract
Autoimmune bullous diseases are a heterogeneous group of disorders that can be subdivided according to the level of split formation in the intraepidermal blistering pemphigus diseases and subepidermal bullous disorders, latter including pemphigoid diseases, epidermolysis bullosa acquisita, and dermatitis herpetiformis. In the majority of autoimmune bullous disorders, disease activity can be sufficiently controlled by systemic corticosteroids in combination with further immunosuppressants/immunomodulants such as dapsone, doxycycline, methotrexate, azathioprine, or mycophenolate mofetil. In contrast, in pemphigus, mucous membrane pemphigoid, and epidermolysis bullosa acquisita, treatment is challenging and only in a minority of patients, conventional immunosuppressive therapy induces clinical remission. Since only a few years ago, only cyclophosphamide and high-dose intravenous immunoglobulin were available as potent second-line therapies. Meanwhile, immunoadsorption and the monoclonal anti-CD20 antibody rituximab have been established as further therapeutic options. Here, both conventional therapies and novel treatment regimens for autoimmune blistering diseases are discussed.
Keywords: Epidermolysis bullosa acquisita, immunoadsorption, pemphigus, mucous membrane pemphigoid, rituximab
Current Drug Discovery Technologies
Title: Current Treatment of Autoimmune Blistering Diseases
Volume: 6 Issue: 4
Author(s): Michael Kasperkiewicz and Enno Schmidt
Affiliation:
Keywords: Epidermolysis bullosa acquisita, immunoadsorption, pemphigus, mucous membrane pemphigoid, rituximab
Abstract: Autoimmune bullous diseases are a heterogeneous group of disorders that can be subdivided according to the level of split formation in the intraepidermal blistering pemphigus diseases and subepidermal bullous disorders, latter including pemphigoid diseases, epidermolysis bullosa acquisita, and dermatitis herpetiformis. In the majority of autoimmune bullous disorders, disease activity can be sufficiently controlled by systemic corticosteroids in combination with further immunosuppressants/immunomodulants such as dapsone, doxycycline, methotrexate, azathioprine, or mycophenolate mofetil. In contrast, in pemphigus, mucous membrane pemphigoid, and epidermolysis bullosa acquisita, treatment is challenging and only in a minority of patients, conventional immunosuppressive therapy induces clinical remission. Since only a few years ago, only cyclophosphamide and high-dose intravenous immunoglobulin were available as potent second-line therapies. Meanwhile, immunoadsorption and the monoclonal anti-CD20 antibody rituximab have been established as further therapeutic options. Here, both conventional therapies and novel treatment regimens for autoimmune blistering diseases are discussed.
Export Options
About this article
Cite this article as:
Kasperkiewicz Michael and Schmidt Enno, Current Treatment of Autoimmune Blistering Diseases, Current Drug Discovery Technologies 2009; 6 (4) . https://dx.doi.org/10.2174/157016309789869065
DOI https://dx.doi.org/10.2174/157016309789869065 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Prospects for Parathyroid Hormone and Parathyroid Hormone Analogs
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Managing Comorbidity in COPD: A Difficult Task
Current Drug Targets Lifestyle Modification for Masked Hypertension
Current Hypertension Reviews Potential Therapeutic Interest of Adenosine A2A Receptors in Psychiatric Disorders
Current Pharmaceutical Design An Unusual Case of Reversible Empty Sella
Endocrine, Metabolic & Immune Disorders - Drug Targets Clinical Efficacy of Remdesivir and Favipiravir in the Treatment of COVID-19 Patients: Scenario so far
Current Drug Research Reviews Diabetes-Induced Alterations in Renal Medullary Microcirculation and Metabolism
Current Diabetes Reviews Is It Possible to Apply Secondary Stroke Prevention Guidelines to Very Old Populations?
Cardiovascular & Hematological Disorders-Drug Targets Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments
Current Medicinal Chemistry Maternal Outcomes in Women with Major Degree Placenta Previa: An Observational Cohort Study
Current Women`s Health Reviews Update in Glaucoma Medicinal Chemistry: Emerging Evidence for the Importance of Melatonin Analogues
Current Medicinal Chemistry NO News is not Necessarily Good News in Cancer
Current Cancer Drug Targets Machine Learning Approaches in Parkinson’s Disease
Current Medicinal Chemistry Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology Cannabinoids as Neuroprotective Agents in Traumatic Brain Injury
Current Pharmaceutical Design Functional Chemical Groups that May Likely Become a Source for the Synthesis of Novel Central Nervous System (CNS) Acting Drugs
Central Nervous System Agents in Medicinal Chemistry Vasoactive Renal Factors and the Progression of Diabetic Nephropathy
Current Pharmaceutical Design Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies
Current Drug Targets Novel Immunotherapies for Hematological Malignancies
Current Molecular Pharmacology Cellular Mechanisms in Perinatal Hypoxic-Ischemic Brain Injury
Current Pediatric Reviews